Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that the Company has entered into a non‑binding letter of intent (the “LOI”) with a South Korean pharmaceutical company to review and evaluate the potential in‑licensing and development of Jyong Biotech’s plant-derived new drug MCS-2for the Korean market. The prospective partner is a recognized supplier to both general hospitals and clinics, and the LOI reflects mutual interest in assessing commercial and regulatory pathways for introducing MCS products in Korea.

Read more at globenewswire.com